Biopharma India Capacity Growth Modeler

Base Lab Customers 1,200

500 labs 3,000 labs

Annual Growth Rate Target 18.0%

10% 15-20% Target 30%

CDMO Shift Rate 18.0%

5% (Research) 40% (Commercial)

Avg Consumable Spend/Lab $150,000

$50k $300k

Year 3 Customer Pipeline

2,020

▲ +68.3% total expansion

Hyderabad Peak Hub Capacity

808 labs

40% cluster allocation

Total Consumable Market

$303.0M

Reagents & Single-use Bags

Estimated CDMO Batch Demand

1,818 batches

Based on 18.0% manufacturing shift

5-Year Lab Expansion Trajectory

Baseline vs 15%-20% Accelerated Target Comparison

1-5 Year Projection

• Min Band (15%): 1,825 labs @ Yr 3 • Target Selected: 2,020 labs @ Yr 3 • Max Band (20%): 2,074 labs @ Yr 3

Regional Cluster Capacity

Distribution across major Indian Biopharma Hubs

Hyderabad (Biologics & CDMO Hub) 40%

Labs: 808 Est. Spend: $121.2M

Bengaluru (R&D & Gene-to-Protein) 35%

Labs: 707 Est. Spend: $106.1M

Pune-Mumbai (Pharma & Fill-Finish) 25%

Labs: 505 Est. Spend: $75.8M

Workflow Impact: Cluster weight shifts reallocate single-use bioreactor bag inventory and gene-to-protein purification columns in real-time.

Bioprocessing Equipment & Consumable Volume Forecast

Single-Use Bioprocess Bags

10,100 units/yr

5 units per lab customer/yr average

Gene-to-Protein Kits

24,240 kits/yr

12 kits per research customer/yr

HPLC / Mass Spec Units

505 instruments

1 analytical unit per 4 labs

CapEx Allocation Target

$60.6M

Estimated lab infrastructure capital

Model Summary & Strategy Export

Biopharma India Capacity Growth Modeler

Validated against Thermo Fisher's 15%-20% customer growth target for Indian research and manufacturing expansion.

Active Simulation State: COMPUTED_OPTIMAL

Yr 3 Customers: 2,020

Hyderabad Labs: 808

Consumable Spend: $303.0M

CDMO Batches: 1,818

Growth Rate: 18.0%

Base Customers: 1,200